VYVANSE
Pronunciation: lis-dex-am-FET-a-meen (VYE-vans)


What it isCatecholamine-releasing dextroamphetamine prodrug; ADHD and binge-eating disorder.
Why this oneEnzymatic activation produces a slower rise and makes tampering less rewarding than with immediate-release amphetamine.
What limits itAppetite suppression, insomnia, tachycardia and blood-pressure rise can end treatment. Diversion and dependence still matter.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| ADHD | Adults & pediatric >=6 yr | 30 mg QAM | 30–70 mg/day (titrate 10–20 mg weekly) | 70 mg/day |
| Moderate to severe binge eating disorder (BED) | Adults | 30 mg QAM (titrate 20 mg weekly) | 50–70 mg/day | 70 mg/day |
Titration Adjust at approximately weekly intervals (ADHD: 10–20 mg; BED: 20 mg).
Renal Severe impairment (GFR 15–<30): max 50 mg/day; ESRD (GFR <15): max 30 mg/day; not dialyzable
Hepatic Undefined
Available strengths
Pregnancy Insufficient human data; amphetamine use is associated with premature delivery and low birth weight; monitor neonates for withdrawal.
Lactation Present in human milk; breastfeeding is not recommended during treatment.
| Strength | #/mo | generic $/mo | CostPlus | |
|---|---|---|---|---|
| 10 mg | cap | 4 q-wk | $10.50 | not offered |
| 20 mg | cap | 4 q-wk | $9.75 | not offered |
| 30 mg | cap | 4 q-wk | $10.80 | not offered |
| 40 mg | cap | 4 q-wk | $10.41 | not offered |
| 50 mg | cap | 4 q-wk | $10.56 | not offered |
| 60 mg | cap | 4 q-wk | $10.69 | not offered |
| 70 mg | cap | 4 q-wk | $10.70 | not offered |
| 10 mg | chew tab | 4 q-wk | $14.95 | not offered |
| 20 mg | chew tab | 4 q-wk | $17.35 | not offered |
| 30 mg | chew tab | 4 q-wk | $13.17 | not offered |
| 40 mg | chew tab | 4 q-wk | $15.92 | not offered |
| 50 mg | chew tab | 4 q-wk | $14.59 | not offered |
| 60 mg | chew tab | 4 q-wk | $14.58 | not offered |
Generic entry2023
⚠ BOXED WARNING
Legacy pregnancy categoryC
Defining liabilityCardiovascular stimulation, appetite suppression, insomnia, misuse and stimulant-induced psychosis.
Provisional washout figures
Elevating mechanismNone identified
Non-elevating actionNone recorded
Exposure dependenceNo serotonin-elevating mechanism identified
Evidence confidenceModerate
InterpretationNo clinically meaningful serotonin-elevating mechanism identified in this first-pass Gillman-based review.